17 completed, 11 terminated, 11 unknown, 5 active not recruiting. 53 Phase 2, 14 Phase 1, 2 Phase 3.
Follow Castration-resistant Prostate Cancer: new trials by email Literature Review of Castration-resistant Prostate Cancer trials Research Report on Castration-resistant Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer BL-B01D1, Abiraterone, Olaparib - Castration-resistant Prostate Cancer | Phase 2 / Phase 3 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 180 | 2026-09-01 | 2026-07-23 |
| Study of Oral MRT-2359 With Apalutamide in Prostate Cancer Oral MRT-2359, Apalutamide - Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer | Phase 2 | Recruiting | Monte Rosa Therapeutics, Inc | 25 | 2026-08-18 | 2026-10-08 |
| A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC 161Tb RAD402 - Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Recruiting | Radiopharm Theranostics, Ltd | 73 | 2026-03-05 | 2026-04-01 |
| 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer 177Lu-PSMA-617, Niraparib abiraterone acetate, Prednisone - Metastatic Prostate Cancer, Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Withdrawn | Baptist Health South Florida | 2024-10-01 | 2024-09-19 | |
| Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial Abiraterone, Apalutamide, Biospecimen Collection - Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer | Phase 2 | Recruiting | Mayo Clinic | 532 | 2024-06-03 | 2026-07-20 |
| Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer Disitamab Vedotin Injection - Castration-resistant Prostate Cancer | Phase 2 | Unknown | RemeGen Co., Ltd. | 40 | 2024-04-08 | 2024-05-23 |
| Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID) Stereotactic body radiotherapy, Adebrelimab - Prostate Cancer Metastatic, Castration-resistant Prostate Cancer | Phase 2 | Unknown | Fudan University | 30 | 2024-01-30 | 2024-02-20 |
| Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc AR Blockade, Carotuximab - Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Edwin Posadas, MD | 116 | 2023-12-27 | 2026-10-05 |
| Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer Olaparib, Vitamin C - Prostate Cancer, Castration-resistant Prostate Cancer | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 4 | 2023-06-30 | 2025-01-29 |
| Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer Cabozantinib, Nivolumab - Castration-resistant Prostate Cancer, Metastatic Cancer | Phase 2 | Active not recruiting | Rana McKay, MD | 47 | 2023-02-02 | 2026-09-08 |
| A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors Nanrilkefusp Alfa, Pembrolizumab - Non-Small Cell Lung Cancer, Colorectal Cancer | Phase 2 | Terminated | SOTIO Biotech AG | 166 | 2022-06-21 | 2025-11-17 |
| Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer Testosterone Undecanoate, Enzalutamide - Prostate Cancer, Castration-resistant Prostate Cancer | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 15 | 2022-03-07 | 2026-09-29 |
| A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours HMBD-001, HMBD-001 and enzalutamide - Bladder Cancer, Triple Negative Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | Cancer Research UK | 81 | 2021-11-10 | 2025-08-11 |
| Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer Neratinib - Metastatic Prostate Adenocarcinoma, Castration-resistant Prostate Cancer | Phase 2 | Withdrawn | Beth Israel Deaconess Medical Center | 2021-05-21 | 2023-07-11 | |
| The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC Coenzyme A Combined With Abiraterone, Abiraterone - Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Unknown | Jiangnan University | 50 | 2021-03-18 | 2021-04-09 |
| Polaprezinc Treatment for Enzalutamide- or Abiraterone-resistant CRPC Polaprezinc group, Control group - Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Completed | Jiangnan University | 12 | 2021-01-06 | 2023-07-11 |
| Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X) Darolutamide (BAY1841788), SBRT - Metastatic Prostate Cancer, Castration-resistant Prostate Cancer | Phase 2 | Active not recruiting | Sir Mortimer B. Davis - Jewish General Hospital | 66 | 2020-10-19 | 2026-05-27 |
| A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate Cancer nab-paclitaxel, carboplatin - Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Unknown | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 44 | 2019-11-01 | 2019-11-04 |
| pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer pTVG-HP, pTVG-AR, Pembrolizumab - Castration-resistant Prostate Cancer, Metastatic Cancer | Phase 2 | Active not recruiting | University of Wisconsin, Madison | 60 | 2019-10-21 | 2026-08-26 |
| Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide Docetaxel, Enzalutamide - Prostate Cancer, Castration-resistant Prostate Cancer | Phase 2 | Unknown | Instituto do Cancer do Estado de São Paulo | 30 | 2019-09-03 | 2024-04-15 |
Showing 20 of 53. Sign in to see all of them.
Prostatic Neoplasms (26) · Neoplasm Metastasis (5) · Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (2) · Ovarian Neoplasms (2) · Adenocarcinoma (1) · Breast Neoplasms (1) · Bulbo-Spinal Atrophy, X-Linked (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Fibromatosis, Gingival, 2 (1) · Lethal Congenital Contracture Syndrome 2 (1) · Melanoma (1) · Neoplastic Cells, Circulating (1)
Neoplasms (31) · Neoplasms by Site (29) · Genital Diseases (28) · Urogenital Diseases (28) · Urogenital Neoplasms (28) · Genital Diseases, Male (27) · Genital Neoplasms, Male (27) · Male Urogenital Diseases (27) · Prostatic Diseases (27) · Neoplastic Processes (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Carcinoma (3) · Neoplasms by Histologic Type (3) · Neoplasms, Glandular and Epithelial (3)
enzalutamide (11) · Abiraterone Acetate (6) · Docetaxel (5) · Prednisone (4) · abiraterone (4) · Nivolumab (3) · apalutamide (3) · pembrolizumab (3) · Carboplatin (2) · Radiosurgery (2) · Testosterone Propionate (2) · cabazitaxel (2) · cabozantinib (2) · darolutamide (2) · olaparib (2)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · Innocrin Pharmaceutical (2) · Jiangnan University (2) · Jiangsu HengRui Medicine Co., Ltd. (2) · Taro Iguchi, MD, PHD (2) · Asan Medical Center (1) · Astellas Pharma Europe B.V. (1) · Baptist Health South Florida (1) · Bayer (1) · Beth Israel Deaconess Medical Center (1) · Cancer Research UK (1) · Cancer Trials Ireland (1) · Centre Francois Baclesse (1) · Consorzio Oncotech (1) · Dana-Farber Cancer Institute (1)
United States (24) · China (8) · France (6) · United Kingdom (4) · Canada (3) · Czechia (3) · Australia (2) · Georgia (2) · Hungary (2) · Italy (2) · Japan (2) · Poland (2) · Russia (2) · Belgium (1) · Brazil (1)
Adrian VS Hill (1) · Andrew Protheroe (1) · Anthony Joshua, MD,MBBS,PhD,FRACP (1) · Anthony M Joshua, MBBS, PhD, FRACP (1) · Celestia S Higano, MD (1) · Channing Paller, MD (1) · David Einstein, MD (1) · Dingwei Ye, M.D. (1) · Diogo Bastos (1) · Douglas McNeel, MD, PhD (1) · Edwin Posadas, MD FACP (1) · Freddie Hamdy (1) · Giuseppe Giuseppe, MD (1)
PMID 26854432, PMID 29590007, PMID 31082669, PMID 31564004, PMID 32203306, PMID 34197212, PMID 34845502, PMID 37058234, PMID 38167882, PMID 38425504, PMID 40906325, PMID 42031429, PMID 42117295
2017 (2), 2016 (1), P30CA015704 (1), R01CA286127 (1), R01CA300454 (1)